SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...

Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per share, compared to net income of $0.5 million, or $4.86 per share, for the ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...